STOCKHOLM, May 16, 2017 /PRNewswire/ --
Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.
Oncoinvent is pleased to announce today that the results of a collaboration between Oncoinvent and Sciencons researchers have been published in the Journal of Nuclear Medicine and Biology.
Alpha-particles have the potential to kill tumor cells very effectively and selectively. The radioisotope 212Pb, which causes the release of alpha-particle, has a half-life of 10.6 h which imposes time constraints to its practical application as a radioimmunoconjugate for cancer therapy. The focus of the published research was to determine whether a rapid, efficient, and reliable production and purification procedure for generating a 212Pb based radioimmunoconjugate could be developed.
The current work demonstrates the feasibility of using a 224Ra solution as a shippable generator solution for producing 212Pb-based radioimmunoconjugates, which may be easier to execute and less time-consuming for the end user in comparison with existing ion exchange based methods.
A free access copy of the article can be obtained through the online version of the journal: http://www.sciencedirect.com/science/journal/09698051
For further information, please contact:
Jan A. Alfheim,
Chief Executive Officer
Ole Peter Nordby,
Chief Financial Officer
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Oncoinvent AS